Overview
In this episode, Aaron and Jamie discuss three articles at different levels of evidence: a report on autism research using nonhuman primates and the infrastructure supporting it; a caregiver/clinical commentary reframing children’s “lack of effort” as a possible executive-function skills gap; and an overview of the FDA-approved ADHD medication Simtriyo (centanafadine), including trial results, side effects, and limits. The hosts stress keeping model research, clinical commentary, and medication trial data distinct.
Autism research involving monkeys contends with uphill battle
The Transmitter, by Diana Kwon, dated November 2, 2026.
- The article is part of a series asking what happens if nonhuman primate research goes away. Its central claim is that macaques and marmosets can model some core autism traits better than mice can, but U.S. funding uncertainty and changes at primate centers threaten that work.
- David Amaral’s team at the University of California, Davis, has worked with collaborators at the Oregon National Primate Research Center since 2020 to create a macaque with a CHD8 variant. In September 2025, they celebrated the birth of their first such animal. CHD8 is linked to autism and co-occurring intellectual disability and macrocephaly. Amaral estimates they need 10 genetically modified monkeys to adequately explore the causes of megalencephaly, the brain overgrowth condition. The team has been genotyping and phenotyping the first animal, logging behavioral records and longitudinal MRI scans, and creating a second.
- After negotiations earlier in the year about potentially converting the Oregon center into an animal sanctuary, the facility plans to downsize and pivot to nonanimal models. It is unclear which monkey research will continue. The center has an artificial reproductive technology core that does not exist at other U.S. primate centers, and Amaral says it is essential to his project. The team is proceeding as if the center will keep producing genetically modified macaques, but losing access could end the project prematurely.
- The article reports more than half a dozen monkey models of autism and related conditions, based on natural social variation, maternal infection, and genetic modification, with more in the works. Researchers worry about maintaining international collaborations, resources, and technical expertise. Michael Platt says funding cuts and delays could require letting go of people with specialized expertise or depopulating a primate colony, and rebuilding after those losses would be extremely difficult. Amaral says it is hard to be optimistic and that attracting younger investigators to this work would be a very hard sell.
- Guoping Feng at MIT says a growing body of evidence suggests monkey models can address some limitations of other animal models. Mice lack some autism-linked brain regions, such as the dorsolateral prefrontal cortex, and do not reliably model social deficits. The article describes SHANK3 macaques created with researchers at the Shenzhen Institutes of Advanced Technology. Heterozygous SHANK3 monkeys—carrying one altered copy of the gene—unlike heterozygous SHANK3 mice, show sleep disturbances, abnormal social interactions, cognitive impairment, repetitive behaviors, and altered functional connectivity in the brain that parallel features seen in people carrying SHANK3 variants.
- The hosts emphasize that this is model work, not a claim that a monkey has autism in the human sense. It is meant to study mechanisms and test interventions. Feng says they are not claiming a monkey model is required for clinical trials, but these studies give confidence that treatments are safe and effective. His SHANK3 minigene therapy has been licensed to Jaguar Gene Therapy, which is investigating it in a clinical trial. Feng also says, “No model is perfect. Not even a human is a perfect model for another human.”
- Researchers are also turning to lab-grown organoids and other in-vitro models, plus recordings taken during surgery in people, but some studies, such as gene therapy testing, require living animals at least for the time being.
- Nonhuman primate neuroscience remains active in China and Japan. The China Brain Project, a 5 billion yuan initiative launched in 2022—about $750 million—put nonhuman primate studies at its core. Japanese policymakers have generally supported primate work, and Noritaka Ichinohe says nonhuman primate research is still quite active there even though the latest national brain project emphasizes human research more. His group developed a marmoset model of autism based on valproic acid exposure.
- Robert Desimone at MIT says the SHANK3 macaques remain in China because MIT, like most U.S. institutions other than the seven federally supported primate research centers, lacks the space and facilities to house the large numbers needed. He says macaque transgenic work is very difficult in the U.S.; marmoset work is expensive but much more feasible because the animals are smaller and easier to handle and breed.
- Zhonghua Lu says the latest SHANK3 monkey study, which collected extensive behavioral phenotypes and neuroimaging data for 15 animals, required eight full-time technicians and engineers. Even in China, funds for primate projects can be increasingly difficult to obtain, particularly as the government favors brain-computer interface research.
- The hosts frame this as a long-horizon story with real uncertainty and an ongoing ethical debate, rather than either “this is the answer” or “this is pointless.” The article reports concerns but does not resolve what will happen at Oregon or in the field. For families, the hosts say the story is less about a treatment tomorrow and more about the research pipeline, the questions scientists can ask, and whether the next generation gets trained.
“What Your Child’s Lack of Effort Is Really About”
ADDitude caregiver blog by Debbie Bolger, LMHC, updated October 21, 2026.
- The hosts label this as a clinical commentary and caregiver blog, not a peer-reviewed study. Bolger argues that getting things done is not one skill. It involves interest or motivation, initiation, sustained effort, and follow-through. The last three rely heavily on executive functions. A child can be fully interested and still stall at initiation or follow-through.
- Bolger says that when she talks with children, they often do not dispute the observable facts. They report that when something gets hard or boring, staying with it is genuinely difficult. So “doesn’t care” is often the wrong explanation, and “skills gap” is more useful.
- The suggested reframe is moving from “my child doesn’t care” to “my child finds this genuinely harder than most; there’s a skill here that needs to be built.” The hosts say this lowers the temperature without meaning there are no expectations; it changes the support.
- Bolger describes a documented difference in how ADHD brains respond to delayed rewards: distant rewards are discounted more steeply, with reduced activation in reward circuitry when a payoff is not immediate. A test weeks away rarely creates a pull to start studying now. The article does not name a specific study or citation for that claim, so the hosts treat it as her summary of a broader literature, not a new finding.
- For initiation, she suggests shrinking the entry point—such as “read for five minutes” or “get the instrument out of the case” instead of “study for half an hour” or “practice.” She also suggests naming the feeling behind avoidance, like “I’m overwhelmed” or “I’m dreading this,” and habit stacking, pairing an unpreferred activity with a fixed anchor, such as organizing backpacks right after dinner.
- For sustained effort and follow-through, she suggests clear endpoints, a short immediate reward after a stretch of effort, alternating about 10 minutes of hard focus with breaks, external scaffolding such as a visible checklist, a body double, or a gentle check-in, and teaching recovery after attention lapses rather than perfect concentration.
- The hosts note that these are clinical suggestions. The article does not report outcome data or compare their effectiveness, so families can try what fits, but it is not a proven protocol. The examples come from the author’s correspondence and sessions and are anecdotal, not systematic data. The useful shift may be asking which component is breaking down: starting, sustaining, or returning after interruption. The article focuses on children, though the hosts note the same components can apply to adults.
Simtriyo (centanafadine)
ADDitude article by Melanie Wolkoff Wachsman, updated October 12, 2026.
- The article profiles Simtriyo, generic centanafadine. The FDA approved it in July 2026 for ADHD in adults and pediatric patients aged 6 years and older weighing at least 44 pounds, or 20 kilograms.
- It is described as a first-in-class norepinephrine, dopamine, serotonin reuptake inhibitor—meaning it blocks the reabsorption of those three neurotransmitters. It is also a central nervous system stimulant, taken once daily as an extended-release capsule. At the time of the article, it was pending Drug Enforcement Administration scheduling and expected to be available in late 2026.
- It is described as the first approved ADHD medication designed to simultaneously target all three of those neurotransmitters. The approval was supported by four Phase 3 trials plus a 52-week adult extension study.
- In the pediatric trials—480 children and 459 adolescents over six weeks—about half of adolescents on high-dose centanafadine and a third of children on high dose had an 18-point or greater reduction on the ADHD Rating Scale–5, compared with 23% in the placebo group. Low-dose centanafadine did not produce statistically significant improvements in the pediatric trials.
- The article describes two adult randomized trials. In an adult Phase 3 trial involving 859 adults aged 18 to 55, one-quarter of those on either low- or high-dose centanafadine had an 18-point or greater reduction on the Adult ADHD Investigator Symptom Rating Scale, compared with 15.4% on placebo.
- The most common side effects in adults were headache, decreased appetite, insomnia, nausea, dry mouth, and diarrhea. In children 6 to 12, they were rash and decreased appetite; in adolescents, decreased appetite, nausea, rash, headache, and abdominal pain. The article notes contraindications and interactions, including monoamine oxidase inhibitors, or MAOIs, other stimulants, some mood medications, and others.
- The hosts stress that this is group-level data. It does not mean everyone responds, and it does not tell a family what is right for them. The article is not a recommendation; families should talk with the prescriber.
- The 52-week extension study reported long-term safety and tolerability, and the authors concluded centanafadine is safe and effective for long-term treatment of adults with ADHD. The hosts say that should not become a blanket claim for everyone. The article also notes that AISRS total scores increased by up to 57% in adults who took 400 mg twice daily; the hosts say they would want to read the original paper before interpreting that detail.
Podcast Transcript
Aaron: Welcome to Living on the Spectrum. I’m Aaron, and with me is Jamie. Today we’re starting with a story about autism research in monkeys—not because monkeys are stand-ins for autistic people, but because scientists are trying to answer some very specific biological questions, and the infrastructure behind that work may be changing.
Jamie: Thanks, Aaron. The piece is by Diana Kwon in The Transmitter, dated November 2, 2026. It’s part of a series asking what happens if nonhuman primate research goes away. The central claim is that macaques and marmosets can model some core autism traits better than mice can, but U.S. funding uncertainty and changes at primate centers threaten that work.
Aaron: Can you give the concrete example? Because this can sound very abstract.
Jamie: Yes. David Amaral’s team at the University of California, Davis, worked with collaborators at the Oregon National Primate Research Center since 2020 to create a macaque with a CHD8 variant. In September 2025 they celebrated the birth of their first such animal. CHD8 is linked to autism and co-occurring intellectual disability and macrocephaly. Amaral estimates they need 10 genetically modified monkeys to adequately explore the causes of megalencephaly—the brain overgrowth condition. They’ve been genotyping and phenotyping the first animal, logging behavioral records and longitudinal MRI scans, and creating a second.
Aaron: And the Oregon center is central to that.
Jamie: It is. After negotiations earlier in the year about potentially converting the Oregon center into an animal sanctuary, the facility plans to downsize and pivot to nonanimal models. It’s unclear which monkey research will continue. The center has an artificial reproductive technology core that doesn’t exist at other U.S. primate centers, and Amaral says it’s essential to his project. The team is proceeding as if the center will keep producing genetically modified macaques, but losing access could end the project prematurely.
Aaron: So this isn’t just a philosophical debate about animal research. A specific research program hangs on a facility and a specialized team.
Jamie: Right. The article says there are now more than half a dozen monkey models of autism and related conditions, based on natural social variation, maternal infection, and genetic modification, and more are in the works. Researchers worry about maintaining international collaborations, resources, and technical expertise. Michael Platt, who studies social behaviors in monkeys, says funding cuts and delays could require letting go of people with specialized expertise or depopulating a primate colony, and rebuilding after those losses would be extremely difficult. Amaral says it’s hard to be optimistic and that attracting younger investigators to this work would be a very hard sell.
Aaron: Why monkeys at all? I think listeners hear “mice” and “monkeys” and wonder what difference it makes.
Jamie: Guoping Feng at MIT says a growing body of evidence suggests monkey models can address some limitations of other animal models. Mice lack some autism-linked brain regions, such as the dorsolateral prefrontal cortex, and they don’t reliably model social deficits. The article describes SHANK3 macaques created in collaboration with researchers at the Shenzhen Institutes of Advanced Technology. Heterozygous SHANK3 monkeys—meaning they carry one altered copy of the gene—unlike heterozygous SHANK3 mice, show sleep disturbances, abnormal social interactions, cognitive impairment, repetitive behaviors, and altered functional connectivity in the brain that parallel features seen in people carrying SHANK3 variants.
Aaron: That’s a strong statement. But I want to be careful: a model is not the same as saying a monkey has autism in the human sense.
Jamie: Exactly. This is model work. It’s meant to study mechanisms and test interventions, not to define autistic people through animals. And the article keeps that distinction: Feng says they aren’t claiming a monkey model is required for clinical trials, but these studies give confidence that treatments are safe and effective. His SHANK3 minigene therapy has been licensed to Jaguar Gene Therapy, which is investigating it in a clinical trial.
Aaron: So there’s a potential treatment pipeline here, but we shouldn’t imply a headline cure is around the corner.
Jamie: No. And Feng is careful. He says, “No model is perfect. Not even a human is a perfect model for another human.” The article also notes researchers are turning to lab-grown organoids and other in-vitro models, plus recordings taken during surgery in people, but some studies, like gene therapy testing, require living animals at least for the time being.
Aaron: What about the international picture?
Jamie: The article says nonhuman primate neuroscience remains active in China and Japan. The China Brain Project, a 5 billion yuan initiative launched in 2022—about $750 million—put nonhuman primate studies at its core. Japanese policymakers have generally supported primate work, and Noritaka Ichinohe says nonhuman primate research is still quite active there even though the latest national brain project emphasizes human research more. His group developed a marmoset model of autism based on valproic acid exposure.
Aaron: And the U.S. picture is more constrained. Robert Desimone at MIT says the SHANK3 macaques remain in China because MIT, like most U.S. institutions other than the seven federally supported primate research centers, lacks the space and facilities to house the large numbers needed. He says macaque transgenic work is very difficult in the U.S.; marmoset work is expensive but much more feasible because the animals are smaller and easier to handle and breed.
Jamie: Yes. And the costs are huge. Zhonghua Lu says the latest SHANK3 monkey study, which collected extensive behavioral phenotypes and neuroimaging data for 15 animals, required eight full-time technicians and engineers. Even in China, funds for primate projects can be increasingly difficult to obtain, particularly as the government favors brain-computer interface research.
Aaron: So what might this mean in everyday life? For families, I think it’s less about a treatment tomorrow and more about the research pipeline and the questions scientists can ask. Also about whether the next generation gets trained.
Jamie: That’s a fair reading. The article reports concerns but doesn’t resolve what will happen at Oregon or in the field. It’s a long-horizon story with real uncertainty, and it’s also part of a broader ethical debate about animal models. We shouldn’t flatten it into either “this is the answer” or “this is pointless.”
Aaron: That leads to a very different article—an ADDitude caregiver blog by Debbie Bolger, LMHC, updated October 21, 2026. It’s called “What Your Child’s Lack of Effort Is Really About.” This felt very everyday.
Jamie: The reframe is useful, but we should label it: it’s a clinical commentary and caregiver blog, not a peer-reviewed study. Bolger argues that getting things done isn’t one skill. It involves interest or motivation, initiation, sustained effort, and follow-through. The last three rely heavily on executive functions. A child can be fully interested and still stall at initiation or follow-through. She says when she talks with children, they often don’t dispute the observable facts—they report that when something gets hard or boring, staying with it is genuinely difficult. So “doesn’t care” is often the wrong explanation, and “skills gap” is more useful.
Aaron: Parents in my world hear “no grit” and “procrastinates.” Bolger suggests changing “my child doesn’t care” to “my child finds this genuinely harder than most; there’s a skill here that needs to be built.” That lowers the temperature. It doesn’t mean there are no expectations—it changes the support.
Jamie: Right. It’s not about letting anyone off the hook; it’s about targeting the breakdown. She describes a documented difference in how ADHD brains respond to delayed rewards—that distant rewards are discounted more steeply, with reduced activation in reward circuitry when a payoff isn’t immediate. A test weeks away rarely creates a pull to start studying now. But the article doesn’t name a specific study or citation for that claim, so I’d treat it as her summary of a broader literature, not a new finding.
Aaron: What strategies does she offer?
Jamie: For initiation, she suggests shrinking the entry point—like “read for five minutes” or “get the instrument out of the case” instead of “study for half an hour” or “practice.” Naming the feeling behind avoidance, like “I’m overwhelmed” or “I’m dreading this.” Habit stacking, pairing an unpreferred activity with a fixed anchor, like organizing backpacks right after dinner. For sustained effort and follow-through, she suggests clear endpoints, a short immediate reward after a stretch of effort, alternating about 10 minutes of hard focus with breaks, external scaffolding like a visible checklist, a body double, or a gentle check-in. And teaching recovery after attention lapses rather than perfect concentration.
Aaron: The body-double idea is interesting—another person as part of the scaffolding.
Jamie: Yes, and she frames scaffolding as a bridge that makes self-directed effort possible for many kids with ADHD. But these are clinical suggestions. The article doesn’t report outcome data or compare their effectiveness. So families can try what fits, but it’s not a proven protocol. The useful part may be the conversation shift: ask which component is breaking down. Is it starting? Sustaining? Returning after interruption? The answer changes the support.
Aaron: And for adults listening, those same components can apply, though the article focuses on kids. If this sounds familiar, it may be worth reflecting on.
Jamie: Agreed. And the article’s examples come from the author’s correspondence and sessions—they’re anecdotal, not systematic data.
Aaron: The third piece is a new ADHD medication. An ADDitude article by Melanie Wolkoff Wachsman, updated October 12, 2026, profiles Simtriyo, generic centanafadine. The FDA approved it in July 2026 for ADHD in adults and pediatric patients aged 6 years and older weighing at least 44 pounds, or 20 kilograms. It’s a first-in-class norepinephrine, dopamine, serotonin reuptake inhibitor—meaning it blocks the reabsorption of those three neurotransmitters. It’s also a central nervous system stimulant, taken once daily as an extended-release capsule. At the time of the article it was pending Drug Enforcement Administration scheduling and expected to be available in late 2026. What’s notable?
Jamie: It’s the first approved ADHD medication designed to simultaneously target all three of those neurotransmitters. The approval was supported by four Phase 3 trials plus a 52-week adult extension study. In the pediatric trials—480 children and 459 adolescents over six weeks—about half of adolescents on high-dose centanafadine and a third of children on high dose had an 18-point or greater reduction on the ADHD Rating Scale–5, compared with 23% in the placebo group. The article describes two adult randomized trials; in an adult Phase 3 trial involving 859 adults aged 18 to 55, one-quarter of those on either low- or high-dose centanafadine had an 18-point or greater reduction on the Adult ADHD Investigator Symptom Rating Scale, compared with 15.4% on placebo. The article also says low-dose centanafadine did not produce statistically significant improvements in the pediatric trials.
Aaron: So this is group-level data. It doesn’t mean everyone responds, and it doesn’t tell a family what’s right for them.
Jamie: Exactly. The most common side effects in adults were headache, decreased appetite, insomnia, nausea, dry mouth, and diarrhea. In children 6 to 12, rash and decreased appetite; in adolescents, decreased appetite, nausea, rash, headache, and abdominal pain. There are contraindications and interactions—including monoamine oxidase inhibitors, or MAOIs, other stimulants, some mood medications, and others. This isn’t a recommendation. Families should talk with the prescriber.
Aaron: And the 52-week extension? The article says the authors concluded the medication is safe and effective for long-term treatment in adults. There was also a detail that AISRS total scores increased by up to 57% in adults who took 400 mg twice daily, which sounds like something I’d want to read in the original paper before interpreting.
Jamie: I agree. That’s a good example of why we keep the distinction between what the article reports and a clinical conclusion. The extension study reported long-term safety and tolerability, and the authors concluded centanafadine is safe and effective for long-term treatment of adults with ADHD. But we shouldn’t turn that into a blanket claim for everyone.
Aaron: So three threads today: primate models are a long-horizon research story with real uncertainty and ethical debate; the ADHD effort piece gives a practical reframe but is clinical commentary; and the new drug is a genuine approval with trial data but not a universal answer.
Jamie: Yes. And they’re at different levels of evidence. The effort blog is a framework for conversations; the drug article covers an FDA-approved product with trials; the primate article is about research infrastructure and model limitations. Keeping those separate matters.
Aaron: Thanks for listening to Living on the Spectrum. Links to the articles are on the episode page.
Jamie: Thanks, everyone. Take care.
